Analysts have been eager to weigh in on the Healthcare sector with new ratings on FibroGen (FGEN), VBI Vaccines (VBIV) and Brainsway (BWAY).
FibroGen (FGEN)
In a report released today, Danielle Brill from Raymond James maintained a Sell rating on FibroGen. The company’s shares closed last Wednesday at $41.53.
According to TipRanks.com, Brill is a 5-star analyst with an average return of 21.3% and a 62.6% success rate. Brill covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Sarepta Therapeutics.
FibroGen has an analyst consensus of Moderate Buy, with a price target consensus of $81.00.
See today’s analyst top recommended stocks >>
VBI Vaccines (VBIV)
Raymond James analyst Steven Seedhouse maintained a Buy rating on VBI Vaccines today. The company’s shares closed last Wednesday at $2.77.
According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of 15.6% and a 53.1% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Apellis Pharmaceuticals, and Alexion Pharmaceuticals.
Currently, the analyst consensus on VBI Vaccines is a Strong Buy with an average price target of $6.00.
Brainsway (BWAY)
Raymond James analyst Jayson Bedford maintained a Buy rating on Brainsway today and set a price target of $9.00. The company’s shares closed last Wednesday at $6.33, close to its 52-week low of $5.10.
According to TipRanks.com, Bedford is a 5-star analyst with an average return of 15.6% and a 69.8% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Merit Medical Systems, and Integra Lifesciences.
Brainsway has an analyst consensus of Moderate Buy, with a price target consensus of $11.00, which is a 74.6% upside from current levels. In a report released today, Oppenheimer also assigned a Buy rating to the stock with a $13.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
